🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

There's no good argument against transparency in patent cases: ipwatchdog.com/2022/11/29/us-…

Patent megatrolls got a free pass to break the car supply chain when one of their former lobbyists ran the DOJ's antitrust division. Now that he's gone, the free pass needs to go too. news.bloomberglaw.com/us-law-week/pr…

Court filings are supposed to be public by default, but they're shrouded in secrecy in the government's lawsuit against Gilead. Thanks to Chris Morten, the SHIC clinic at Columbia Law School, and PrEP4All, we're trying to change that.

Good news: deeply flawed PTAB decision to deny review won't stand thanks to Director review. Bad news: the Director remanded for the PTAB to consider another reason to deny review without considering the merits of the petition. Decision here: uspto.gov/sites/default/…

Patent cases are goldmines for litigation funders and may be strategic tools for foreign governments. We need more transparency now. dcjournal.com/a-wake-up-call…

Good news doesn't come all that often, but the European Commission's leaked regulations for licensing standard-essential patents suggests good news is combing for licensors, licensees, and consumers (but maybe not for lawyers). piplius.org/news/europesep…

Given the one-sided hearing that happened this week, PIRG's report on patent abuse and drug pricing is more important than ever: pirg.org/resources/the-…

At a recent House oversight hearing, USPTO Director Kathi Vidal said proposals restricting the public's ability to challenge invalid patents came from unnamed "stakeholders." So we filed a FOIA request to find out who's telling the USPTO what to do. piplius.org/news/pipli-req…

Want to learn how the patent system drives up drug prices and what you can do about it? Join the conversation with @waxmanstrategies, Initiative for Medicines, Access & Knowledge, & us this Wednesday at 2pm ET. More info below and registration here: tinyurl.com/RxPatentWebinar

Together, we can protect the public's right to challenge invalid patents that harm countless Americans each year, especially those who depend on heavily patented drugs and medical devices. To submit comments: federalregister.gov/documents/2023… For more info: piplius.org/news/save-the-…

Many aspects of patent law are unclear and confusing. But patent eligibility isn't one of them. One sign eligibility law crystal clear? The fact that big pharma keeps asking Congress to re-write it in their favor instead of asking courts. tillis.senate.gov/2023/6/tillis-…

Another day, another effort to protect invalid patents so that big pharma and foreign patent trolls can make bigger profits off American workers, patients, and consumers. coons.senate.gov/news/press-rel…

Pretty good patent news! It shouldn't take this much work to cut a flawed patent down to harmless size, but mccoysm and Torbjørn Ludvigsen are heroes for doing it. Big congrats and big thanks. 👏🏆🦸

Who really wins when courts decide if patents are valid instead of the USPTO? Law firms. More from alex here: thehill.com/opinion/congre…

Patent Quality Week is back June 26 - July 3! With changes underway in the U.S. patent system, now is the time to learn why patent quality over quantity matters across the innovation ecosystem. Join the conversation: patentqualityweek.engine.is